Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Itraconazole (this asset) | Eli Lilly and Company | P1 | CC · 41 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BBB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Eli Lilly and Company | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Eli Lilly and Company | P3 | BB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Adriamycin | Yonsei University | P3 | BB |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | BB |
| Indocyanine Green | Institut de Cancérologie de Lorraine | P3 | BB |
+42 more in the Endometrial Cancer cohort
Other indications for Itraconazole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fungal Infectious Disease | — | P4 | BB · 68 |
| Retinoblastoma | — | P4 | BB · 68 |
| Wilms Tumor | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Itraconazole in Endometrial Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/itraconazole-endometrial-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →